| http://dbpedia.org/ontology/abstract
|
Pelareorep (previously known under the tra … Pelareorep (previously known under the trademark Reolysin) is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types (including breast, colorectal and pancreatic, as well as multiple myeloma) when administered alone and in combination with other cancer therapies. In April 2015, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to pelareorep for malignant glioma. In May 2017, the FDA granted Fast Track Designation for pelareorep in metastatic breast cancer. Oncolytics Biotech has more than 415 patents for pelareorep issued globally, including more than 60 in the U.S. and 20 in Canada, as well as numerous patents pending worldwide.ell as numerous patents pending worldwide.
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.oncolyticsbiotech.com/ +
|
| http://dbpedia.org/ontology/wikiPageID
|
28902806
|
| http://dbpedia.org/ontology/wikiPageLength
|
15863
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1118597498
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Adaptive_immune_system +
, http://dbpedia.org/resource/Chemokine +
, http://dbpedia.org/resource/Lenalidomide +
, http://dbpedia.org/resource/Pembrolizumab +
, http://dbpedia.org/resource/Paclitaxel +
, http://dbpedia.org/resource/Gemcitabine +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
, http://dbpedia.org/resource/Oncolytics_Biotech +
, http://dbpedia.org/resource/Category:Virotherapy +
, http://dbpedia.org/resource/T_cell +
, http://dbpedia.org/resource/Metastatic_breast_cancer +
, http://dbpedia.org/resource/Ras_subfamily +
, http://dbpedia.org/resource/Natural_killer_cell +
, http://dbpedia.org/resource/Hematological_malignancies +
, http://dbpedia.org/resource/Cytokine +
, http://dbpedia.org/resource/Oncolytic_virus +
, http://dbpedia.org/resource/Food_and_Drug_Administration +
, http://dbpedia.org/resource/Orphan_drug_designation +
, http://dbpedia.org/resource/Immuno-oncology +
, http://dbpedia.org/resource/Mammalian_orthoreovirus +
, http://dbpedia.org/resource/Carboplatin +
, http://dbpedia.org/resource/Virotherapy +
, http://dbpedia.org/resource/Category:Reoviruses +
, http://dbpedia.org/resource/Innate_immune_system +
, http://dbpedia.org/resource/Pomalidomide +
, http://dbpedia.org/resource/Antigen-presenting_cell +
, http://dbpedia.org/resource/Solid_tumors +
, http://dbpedia.org/resource/Malignant_glioma +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Tlx +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Missing_information +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Reoviruses +
, http://dbpedia.org/resource/Category:Virotherapy +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Pelareorep?oldid=1118597498&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Pelareorep +
|
| owl:sameAs |
https://global.dbpedia.org/id/4tokd +
, http://www.wikidata.org/entity/Q7313867 +
, http://dbpedia.org/resource/Pelareorep +
|
| rdfs:comment |
Pelareorep (previously known under the tra … Pelareorep (previously known under the trademark Reolysin) is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types (including breast, colorectal and pancreatic, as well as multiple myeloma) when administered alone and in combination with other cancer therapies.n combination with other cancer therapies.
|
| rdfs:label |
Pelareorep
|
